华东医药：预计于2026年Q4获得揭盲后的顶线数据

Core Viewpoint - East China Pharmaceutical (华东医药) is conducting a Phase 3 clinical trial for HDM1002, focusing on weight management, with results expected in Q4 2026 [1] Group 1 - The clinical trial includes three dosage groups: 200mg, 400mg, and a placebo [1] - The treatment duration is set for 52 weeks, followed by a 4-week safety follow-up, totaling 56 weeks [1] - The company anticipates unblinded top-line data by the end of 2026 [1]